Vantage logo

Recycling pays off for Mereo

The company has spent five years buying in discontinued projects, and at last has managed to sell one of these on at a nice profit.

Vantage logo

Gilead would rather forget filgotinib

The much-heralded Gilead and Galapagos partnership takes a big knock as the US biotech cuts some of its losses with the doomed arthritis project.

Vantage logo

Finding the next Prevail

An $880m buyout by Lilly shows that some gene therapy companies have not yet priced themselves out of the market.

Vantage logo

Alexion ticks Astra’s boxes

The deal solves several problems for Astra, and ranks as biopharma’s fifth-biggest cross-border transaction.

Vantage logo

The pandemic response roars on

As Regeneron’s antibody cocktail becomes the latest Covid-19 treatment to win US authorisation, Merck shows that the search for new options is not over.